UNLABELLED: Preclinical studies suggest that serotonin 1A receptors (5-HT 1A) play a role in temporal lobe epilepsy (TLE). Previous PET studies reported decreased 5-HT 1A binding ipsilateral to epileptic foci but did not correct for the partial-volume effect (PVE) due to structural atrophy. METHODS: We used PET with 18F-trans-4-fluoro-N-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl-N-(2-pyridyl)cyclohexanecarboxamide (18F-FCWAY), a 5-HT 1A receptor antagonist, to study 22 patients with TLE and 10 control subjects. In patients, 18F-FDG scans also were performed. An automated MR-based partial-volume correction (PVC) algorithm was applied. Psychiatric symptoms were assessed with the Beck Depression Inventory Scale. RESULTS: Before PVC, significant (uncorrected P < 0.05) reductions of 18F-FCWAY binding potential (BP) were detected in both mesial and lateral temporal structures, mainly ipsilateral to the seizure focus, in the insula, and in the raphe. Group differences were maximal in ipsilateral mesial temporal regions (corrected P < 0.05). After PVC, differences in mesial, but not lateral, temporal structures and in the insula remained highly significant (corrected P < 0.05). Significant (uncorrected P < 0.05) BP reductions were also detected in TLE patients with normal MR images (n = 6), in mesial temporal structures. After PVC, asymmetries in BP remained significantly greater than for glucose metabolism in hippocampus and parahippocampus. There was a significant inverse relation between the Beck Depression score and the ipsilateral hippocampal BP, both before and after PVC. CONCLUSION: Our study shows that in TLE patients, reductions of 5-HT 1A receptor binding in mesial temporal structures and insula are still significant after PVC. In contrast, partial-volume effects may be an important contributor to 5-HT 1A receptor-binding reductions in lateral temporal lobe. Reduction of 5-HT 1A receptors in the ipsilateral hippocampus may contribute to depressive symptoms in TLE patients.
UNLABELLED: Preclinical studies suggest that serotonin 1A receptors (5-HT 1A) play a role in temporal lobe epilepsy (TLE). Previous PET studies reported decreased 5-HT 1A binding ipsilateral to epileptic foci but did not correct for the partial-volume effect (PVE) due to structural atrophy. METHODS: We used PET with 18F-trans-4-fluoro-N-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl-N-(2-pyridyl)cyclohexanecarboxamide (18F-FCWAY), a 5-HT 1A receptor antagonist, to study 22 patients with TLE and 10 control subjects. In patients, 18F-FDG scans also were performed. An automated MR-based partial-volume correction (PVC) algorithm was applied. Psychiatric symptoms were assessed with the Beck Depression Inventory Scale. RESULTS: Before PVC, significant (uncorrected P < 0.05) reductions of 18F-FCWAY binding potential (BP) were detected in both mesial and lateral temporal structures, mainly ipsilateral to the seizure focus, in the insula, and in the raphe. Group differences were maximal in ipsilateral mesial temporal regions (corrected P < 0.05). After PVC, differences in mesial, but not lateral, temporal structures and in the insula remained highly significant (corrected P < 0.05). Significant (uncorrected P < 0.05) BP reductions were also detected in TLEpatients with normal MR images (n = 6), in mesial temporal structures. After PVC, asymmetries in BP remained significantly greater than for glucose metabolism in hippocampus and parahippocampus. There was a significant inverse relation between the Beck Depression score and the ipsilateral hippocampal BP, both before and after PVC. CONCLUSION: Our study shows that in TLEpatients, reductions of 5-HT 1A receptor binding in mesial temporal structures and insula are still significant after PVC. In contrast, partial-volume effects may be an important contributor to 5-HT 1A receptor-binding reductions in lateral temporal lobe. Reduction of 5-HT 1A receptors in the ipsilateral hippocampus may contribute to depressive symptoms in TLEpatients.
Authors: C C Meltzer; M N Cantwell; P J Greer; D Ben-Eliezer; G Smith; G Frank; W H Kaye; P R Houck; J C Price Journal: J Nucl Med Date: 2000-11 Impact factor: 10.057
Authors: W D Gaillard; L Kopylev; S Weinstein; J Conry; P L Pearl; M V Spanaki; S Fazilat; S Fazilat; L G Venzina; E Dubovsky; W H Theodore Journal: Neurology Date: 2002-03-12 Impact factor: 9.910
Authors: M T Toczek; R E Carson; L Lang; Y Ma; M V Spanaki; M G Der; S Fazilat; L Kopylev; P Herscovitch; W C Eckelman; W H Theodore Journal: Neurology Date: 2003-03-11 Impact factor: 9.910
Authors: R C Knowlton; K D Laxer; G Klein; S Sawrie; G Ende; R A Hawkins; O S Aassar; K Soohoo; S Wong; N Barbaro Journal: Neurology Date: 2001-10-09 Impact factor: 9.910
Authors: R E Carson; L Lang; H Watabe; M G Der; H R Adams; E Jagoda; P Herscovitch; W C Eckelman Journal: Nucl Med Biol Date: 2000-07 Impact factor: 2.408
Authors: Yu Kyeong Kim; Dong Soo Lee; Sang Kun Lee; Seok-Ki Kim; Chun Kee Chung; Ki Hyun Chang; Ki Young Choi; June-Key Chung; Myung Chul Lee Journal: J Nucl Med Date: 2003-07 Impact factor: 10.057
Authors: Richard E Carson; Yanjun Wu; Lixin Lang; Ying Ma; Margaret G Der; Peter Herscovitch; William C Eckelman Journal: J Cereb Blood Flow Metab Date: 2003-02 Impact factor: 6.200
Authors: Andrea Varrone; Nils Sjöholm; Lars Eriksson; Balazs Gulyás; Christer Halldin; Lars Farde Journal: Eur J Nucl Med Mol Imaging Date: 2009-05-13 Impact factor: 9.236
Authors: Giampiero Giovacchini; Robert Bonwetsch; Peter Herscovitch; Richard E Carson; William H Theodore Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-01 Impact factor: 9.236
Authors: Young-Min Lim; Yong-Won Cho; Sadat Shamim; Jeffrey Solomon; Rasmus Birn; Wen Ming Luh; William D Gaillard; Eva K Ritzl; William H Theodore Journal: Epilepsy Res Date: 2008-12 Impact factor: 3.045
Authors: Mohammad Hadi Gharedaghi; Mohammad Seyedabadi; Jean-Eric Ghia; Ahmad Reza Dehpour; Reza Rahimian Journal: Exp Brain Res Date: 2013-11-14 Impact factor: 1.972